BridgeBio Pharma, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
BBIO Nasdaq 2836 bridgebio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BridgeBio Pharma, Inc.

BridgeBio Pharma May Keep Outperforming as Attruby Sales Beat Consensus, Oppenheimer Says - Jul 9th, 2025 8:34 am
Microsoft upgraded, Instacart initiated: Wall Street's top analyst calls - Jul 9th, 2025 7:39 am
High Growth Tech Stocks To Watch In The US July 2025 - Jul 7th, 2025 11:38 am
BridgeBio Pharma Raises $300M Through Partial European Royalty Monetization for BEYONTTRA - Jul 6th, 2025 2:00 am
BridgeBio (BBIO) Tanks After Selling Beyonttra Royalty Rights - Jul 2nd, 2025 8:29 am
BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty - Jun 30th, 2025 5:30 am
BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET - Jun 26th, 2025 5:30 am
TipRanks’ ‘Perfect 10’ Picks: 2 Top-Scoring Stocks That Are Ticking Every Box - Jun 25th, 2025 4:01 am
Piper Sandler Reaffirms Overweight Rating on BridgeBio Ahead of Phase 3 CALIBRATE Results - Jun 24th, 2025 2:25 am
Wolfe Research Initiates Coverage of BridgeBio Pharma (BBIO) with ‘Outperform’ Rating - Jun 20th, 2025 2:04 pm
BridgeBio Pharma, Inc. (BBIO) Price Target Raised to $56 from $53 at H.C. Wainwright - Jun 11th, 2025 5:54 pm
BridgeBio price target raised to $42 from $37 at BMO Capital - Jun 5th, 2025 6:50 am
Exploring High Growth Tech Stocks In The US Market - Jun 4th, 2025 5:38 am
BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 - Jun 2nd, 2025 5:30 am
Rocket Cos., Middleby, Diebold Nixdorf, and More Stocks See Action From Activist Investors - May 23rd, 2025 1:21 pm
BridgeBio’s Acoramidis: A Breakthrough in ATTR-CM Treatment - May 21st, 2025 2:24 am
Are Medical Stocks Lagging Alignment Healthcare (ALHC) This Year? - May 20th, 2025 7:40 am
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM - May 20th, 2025 5:30 am
BridgeBio Pharma Reports Phase 3 Data Linking TTR Increase to Improved Survival With Acoramidis - May 19th, 2025 11:02 am
Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study - May 19th, 2025 10:33 am